Irene da Silva Soares

• Abstract

  A consortium composed by Universidad Peruana Cayetano Heredia, Universidade de São Paulo, Istituto Superiore di Sanità, Université Catholique de Louvain and Medical Research Council Unit aims to contribute for malaria elimination in the Amazon Region. For this, standardized serosurveillance tools will be developed to accurately monitor short and long-term changes in the Plasmodium vivax t…

  Sero-surveillance tools for targeting Plasmodium vivax infections and monitoring malaria control and elimination efforts in Amazonian countries , AP.R

• Abstract

  Plasmodium vivax is the second most prevalent species causing malaria in the world. Recent data estimated 132-391 million cases annually. The relative inefficiency of the measures of control currently used demands the development of new strategies for prevention such as vaccines, new drugs and insecticides. In last the 15 years, studies aimed at the development of a recombinant vaccine ag…

  Generation and analysis of the immunogenicity of recombinant proteins based on the different allelic forms of the circumsporozoite antigen of Plasmodium vivax aiming at the development of a universal vaccine against malaria, AP.TEM

• Abstract

  Malaria is considered one of the priority areas for research and vaccine development. Plasmodium vivax is the most world-widely distributed and the most prevalent specie in America. Attempts to develop malaria vaccines are primarily focused on Plasmodium falciparum and are directed towards reducing morbidity and mortality. The most advanced clinical trials performed with P. vivax vaccine …

  Functional and immunological characterization of Plasmodium vivax RON2 protein, AP.R

(Only some records are available in English at this moment)

• Abstract

  Malaria is an acute febrile infectious disease associated with high morbidity, especially in countries located in the tropical zone of the planet. According to the Pan American Organization, the African region, especially, concentrates around 90% of all malaria cases and deaths worldwide and fifteen countries, of which 14 are located in Sub-Saharan Africa, carry 80% of the global burden o…

  Evaluation of the IgG antibody response against different allelic forms of the Plasmodium vivax circumsporozoite protein in sera from individuals from malaria endemic areas, BP.IC

• Abstract

  Malaria is a disease that threatens public health on a global scale, and in this context,the Amazon region is strongly affected. Several articles describe the resistance of Anopheles mosquitoes to insecticides and drugs used for this disease, generating a global concern. In this scenery, the development of a vaccine against Plasmodium vivax has been considered an efficient alternative. Ho…

  Evaluation of the IgG isotype profile in mice induced by immunization with Plasmodium vivax multi-antigen based formulations, BP.IC

• Abstract

  Malaria is considered a serious problem of public health, which can cause severe forms and lead to death, mainly among children under 5 years of age living in Sub-Saharan Africa. In America, an infection caused by Plasmodium vivax represents 74.1% of cases, currently, according to the Pan American Health Organization. Due to the increase in drug and insecticide resistance, the development…

  Evaluation of the affinity antibodies induced by Plasmodium vivax multi-antigen based formulations in mice, BP.IC

(Only some records are available in English at this moment)

• Abstract

  Plasmodium vivax is the most common species of malaria outside the African continent. The development of an efficacious vaccine would contribute greatly to control of disease transmission. Recently, using bacterial and adenoviral recombinant proteins based on the P. vivax circumsporozoite protein (PvCSP), we demonstrated that it is possible to elicit strong antibody-mediated immune respon…

  Analysis of protective immunity of vaccine formulations against Plasmodium vixax after challenge with P. berghei/P. vivax transgenic parasites in murine model, BE.EP.PD

• Abstract

  Plasmodium vivax is the most world-widely distributed and the most prevalent specie in America. Vaccine development to P. vivax is considered a priority on the global program for the eradication of malaria. In our process linked entitled "Generation of chimeric recombinant proteins for vaccine development against Plasmodium vivax", we hypothesized that an effective vaccine formulation for…

  Functional analyze of murine antibodies induced by immunization with a chimeric recombinant protein based on different immunodominant Plasmodium vivax antigens, BE.EP.IC